426 Shares in Elevance Health, Inc. (NYSE:ELV) Bought by Fountainhead AM LLC

Fountainhead AM LLC acquired a new position in Elevance Health, Inc. (NYSE:ELV) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 426 shares of the company’s stock, valued at approximately $201,000.

Several other institutional investors also recently modified their holdings of the business. GAMMA Investing LLC bought a new stake in shares of Elevance Health in the fourth quarter worth $767,000. Linden Thomas Advisory Services LLC lifted its holdings in Elevance Health by 7.4% in the fourth quarter. Linden Thomas Advisory Services LLC now owns 1,542 shares of the company’s stock valued at $727,000 after buying an additional 106 shares during the period. Community Bank & Trust Waco Texas lifted its holdings in Elevance Health by 7.2% in the fourth quarter. Community Bank & Trust Waco Texas now owns 12,615 shares of the company’s stock valued at $5,949,000 after buying an additional 846 shares during the period. Marks Group Wealth Management Inc acquired a new position in Elevance Health in the fourth quarter valued at $217,000. Finally, RWA Wealth Partners LLC lifted its holdings in Elevance Health by 165.9% in the fourth quarter. RWA Wealth Partners LLC now owns 89,221 shares of the company’s stock valued at $42,073,000 after buying an additional 55,665 shares during the period. Institutional investors own 89.24% of the company’s stock.

Insiders Place Their Bets

In other Elevance Health news, Director Ramiro G. Peru sold 753 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $500.00, for a total value of $376,500.00. Following the completion of the sale, the director now directly owns 9,109 shares of the company’s stock, valued at approximately $4,554,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.29% of the stock is currently owned by insiders.

Elevance Health Stock Up 0.1 %

Shares of ELV traded up $0.70 on Tuesday, reaching $532.92. The company’s stock had a trading volume of 796,340 shares, compared to its average volume of 1,066,078. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.54. Elevance Health, Inc. has a twelve month low of $412.00 and a twelve month high of $539.11. The stock has a market capitalization of $123.86 billion, a PE ratio of 20.14, a PEG ratio of 1.16 and a beta of 0.78. The firm has a fifty day moving average of $510.23 and a 200-day moving average of $485.10.

Elevance Health (NYSE:ELV) last posted its earnings results on Thursday, April 18th. The company reported $10.64 earnings per share for the quarter, topping analysts’ consensus estimates of $10.54 by $0.10. Elevance Health had a net margin of 3.64% and a return on equity of 20.62%. The company had revenue of $42.27 billion for the quarter, compared to analyst estimates of $42.49 billion. During the same quarter in the prior year, the business posted $9.46 EPS. The firm’s revenue was up .9% compared to the same quarter last year. Equities analysts predict that Elevance Health, Inc. will post 37.24 EPS for the current year.

Elevance Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 25th. Shareholders of record on Monday, June 10th will be given a $1.63 dividend. This represents a $6.52 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date is Monday, June 10th. Elevance Health’s payout ratio is 24.64%.

Analyst Ratings Changes

Several equities analysts recently issued reports on ELV shares. Cantor Fitzgerald restated an “overweight” rating and issued a $580.00 target price on shares of Elevance Health in a report on Wednesday, April 10th. Royal Bank of Canada boosted their target price on shares of Elevance Health from $574.00 to $575.00 and gave the company an “outperform” rating in a report on Friday. Truist Financial reiterated a “buy” rating and set a $600.00 price objective (up previously from $580.00) on shares of Elevance Health in a report on Friday. Barclays upped their price objective on shares of Elevance Health from $584.00 to $621.00 and gave the company an “overweight” rating in a report on Friday. Finally, Wells Fargo & Company upped their price objective on shares of Elevance Health from $557.00 to $600.00 and gave the company an “overweight” rating in a report on Friday. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $587.64.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.